Teacher Retirement System of Texas Has $170.67 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Teacher Retirement System of Texas cut its Johnson & Johnson holding by 8.5% in Q4 to 824,669 shares valued at $170,665,000, representing about 0.6% of its portfolio and the fund's 19th-largest position.
• Johnson & Johnson beat Q1 estimates and set FY2026 guidance of $11.45–$11.65 EPS, and the company raised its quarterly dividend to $1.34 (annualized $5.36, ~2.4% yield).
• Insiders sold 30,142 shares (~$7.36M) in the past 90 days, institutional investors own roughly 69.55% of the stock, and analysts' consensus is a "Moderate Buy" with a $252.48 price target.

Teacher Retirement System of Texas lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 824,669 shares of the company's stock after selling 76,206 shares during the period. Johnson & Johnson comprises approximately 0.6% of Teacher Retirement System of Texas' portfolio, making the stock its 19th biggest position. Teacher Retirement System of Texas' holdings in Johnson & Johnson were worth $170,665,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Trail Ridge Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. Trail Ridge Investment Advisors LLC now owns 6,459 shares of the company's stock worth $1,337,000 after buying an additional 84 shares during the period. Cranbrook Wealth Management LLC boosted its position in shares of Johnson & Johnson by 34.2% in the fourth quarter. Cranbrook Wealth Management LLC now owns 4,440 shares of the company's stock worth $919,000 after buying an additional 1,132 shares during the period. West Michigan Advisors LLC boosted its position in shares of Johnson & Johnson by 13.8% in the fourth quarter. West Michigan Advisors LLC now owns 22,345 shares of the company's stock worth $4,624,000 after buying an additional 2,705 shares during the period. Amarillo National Bank boosted its position in shares of Johnson & Johnson by 55.6% in the fourth quarter. Amarillo National Bank now owns 2,269 shares of the company's stock worth $470,000 after buying an additional 811 shares during the period. Finally, Meadow Creek Wealth Advisors LLC boosted its position in shares of Johnson & Johnson by 6.7% in the fourth quarter. Meadow Creek Wealth Advisors LLC now owns 7,769 shares of the company's stock worth $1,608,000 after buying an additional 491 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,142 shares of company stock valued at $7,360,528 in the last ninety days. Insiders own 0.16% of the company's stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and raised guidance — JNJ reported a quarterly revenue and EPS beat and set full‑year 2026 guidance of $11.45–$11.65, reinforcing its earnings trajectory and reducing near‑term execution risk. This is the primary fundamental bullish driver. Johnson & Johnson (JNJ) Exceeds First-quarter Earnings Projections
• Positive Sentiment: Acquisition expands device footprint — JNJ agreed to buy Atraverse Medical to bolster left‑heart access and radiofrequency capabilities in its cardiac device lineup, supporting growth in electrophysiology and procedural devices. Expect modest near‑term cost/integration considerations but potential long‑term revenue upside. Johnson & Johnson to Acquire Atraverse Medical in Cardiac Device Expansion
• Positive Sentiment: Pipeline progress — positive Phase 3/long‑term data for IMAAVY (nipocalimab) in generalized myasthenia gravis and initiation of a head‑to‑head study strengthen JNJ’s autoimmune franchise and de‑risk future revenue potential from this asset. Johnson And Johnson Autoimmune Pipeline Gains With IMAAVY Trial Results
• Positive Sentiment: Strategic partnerships — a commercialization collaboration with Viz.ai to integrate AI subdural hemorrhage detection into JNJ’s neurovascular offerings could accelerate adoption and add software/recurring revenue to device sales. Viz.ai Announces Strategic Collaboration to Expand Access to AI-Powered Subdural Hemorrhage Care
• Neutral Sentiment: TrumpRx listing — JNJ plans to list four prescription drugs on the TrumpRx site. That could increase patient access or volumes but carries political/PR risk and uncertain commercial impact. Johnson & Johnson to launch on TrumpRx with four of its prescription drugs, CBS News reports
• Neutral Sentiment: Positive analyst/commentary pieces — multiple articles frame JNJ as a “value” growth play and a defensive dividend name; helpful for sentiment but not an immediate catalyst. Johnson & Johnson (JNJ): Growth Engine at a Value Price
• Negative Sentiment: Short‑term technical/volume pressure — trading volume is below average, the stock is under its 50‑day moving average, and recent profit‑taking after a strong run may be driving today’s downward move despite the fundamentally positive headlines. (See recent session notes.) JNJ snaps six straight sessions of losses

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Morgan Stanley set a $283.00 target price on Johnson & Johnson in a research report on Wednesday, April 15th. HSBC lifted their price objective on Johnson & Johnson from $265.00 to $280.00 and gave the company a "buy" rating in a research report on Tuesday, March 17th. Freedom Capital cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. Bank of America lifted their price objective on Johnson & Johnson from $253.00 to $254.00 and gave the company a "neutral" rating in a research report on Wednesday, April 15th. Finally, Rothschild & Co Redburn lifted their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the company a "neutral" rating in a research report on Thursday, February 19th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $252.48.

Johnson & Johnson Price Performance

JNJ opened at $227.45 on Monday. The stock has a market cap of $547.53 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 2.23 and a beta of 0.34. Johnson & Johnson has a 1 year low of $146.12 and a 1 year high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a fifty day moving average price of $240.18 and a 200 day moving average price of $218.87.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business's revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Analysts forecast that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be given a $1.34 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is presently 60.12%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.